natgillin/translations-raw huggingface dataset:
Revlimid is used in patients who have a genetic abnormality (called deletion 5q) and are at a lower risk of AML, and it is used when other treatments are not adequate.
Revlimid je indiciran za liječenje bolesnika s genetskom abnormalnosti (naziva delecija 5q) koji su izloženi manjem riziku od AML-a, te kada su druge terapijske mogućnosti neodgovarajuće.
Revlimid lenalidomide
Revlimid lenalidomid
Revlimid may also cause blood clots in the veins (thrombosis).
Revlimid može također prouzročiti nastanak ugrušaka u venama (tromboza).
Revlimid may reduce the number of white blood cells that fight infection and also the blood cells which help the blood to clot (platelets) which may lead to bleeding disorders e.g. nosebleeds and bruising.
Revlimid može smanjiti broj bijelih krvnih stanica koje sprječavaju infekcije te također i broj stanica koje pomažu zgrušavanju krvi (trombociti), što može dovesti do poremećaja krvarenja, npr. krvarenja iz nosa i nastanka modrica.
Revlimid must be given to you by healthcare professionals with experience in treating multiple myeloma or myelodysplastic syndromes and mantle cell lymphoma.
Revlimid Vam moraju dati zdravstveni radnici s iskustvom u liječenju multiplog mijeloma ili mijelodisplastičnih sindroma i limfoma plaštenih stanica.
Revlimid passes into human semen.
Revlimid prolazi u ljudsku spermu.
Revlimid should not be used in children and adolescents from birth to less than 18 years because of safety concerns (see section 4.4).
Revlimid se ne smije primjenjivati u djece i adolescenata, od rođenja pa do 18. godine, zbog sigurnosnih razloga (vidjeti dio 4.4).
Revlimid together with a chemotherapy medicine called ‘melphalan’ and an immunosuppressant medicine called ‘prednisone’.
Revlimid zajedno s kemoterapijskim lijekom pod nazivom ‘melfalan’ i imunosupresivnim lijekom pod nazivom ‘prednizon’.
Revlimid together with an anti-inflammatory medicine called ‘dexamethasone’.
Revlimid zajedno s protuupalnim lijekom pod nazivom ‘deksametazon’
Revlimid treatment should be supervised by a physician experienced in the use of anti-cancer therapies (see section 4.4, karyotype).
Liječenje Revlimidom treba nadzirati liječnik iskusan u primjeni protutumorske terapije (vidjeti dio 4.4, kariotip).
Revlimid treatment should be supervised by a physician experienced in the use of anti-cancer therapies.
Liječenje Revlimidom treba nadzirati liječnik iskusan u primjeni protutumorske terapije.
Revlimid was compared with an appropriate medicine chosen by the patients’ doctors, and the main measure of effectiveness was how long it took until the disease got worse.
Lijek Revlimid uspoređen je s odgovarajućim lijekom koji se odabrali liječnici tih bolesnika, a glavna mjera djelotvornosti bilo je vrijeme do pogoršanja bolesti.
Revlimid was more effective than placebo at preventing a worsening of previously treated multiple myeloma.
Revlimid je bio djelotvorniji od placeba u sprječavanju pogoršanja prethodno liječenog multiplog mijeloma.
Revlimid works by affecting the body’s immune system and directly attacking the cancer.
Revlimid djeluje na imunološki sustav te izravno napada stanice raka.
Revolade 12.5 mg film-coated tablets are round, biconvex, white, debossed with ‘GS MZ1’ and ‘12.5’ on one side.
Revolade 12,5 mg filmom obložene tablete su okrugle, bikonveksne, bijele tablete s utisnutim oznakama ‘GS MZ1’ i ’12,5’ na jednoj strani.
Revolade 25 mg film-coated tablets are round, biconvex, white, debossed with ‘GS NX3’ and ‘25’ on one side.
Revolade 25 mg filmom obložene tablete su okrugle, bikonveksne, bijele tablete s utisnutim oznakama ‘GS NX3’ i ‘25’ na jednoj strani.
Revolade 25 mg powder for oral suspension (eltrombopag)
Revolade 25 mg prašak za oralnu suspenziju (eltrombopag)
Revolade 25 mg powder for oral suspension is available in kits containing 30 sachets; each sachet contains a reddish-brown to yellow powder.
Revolade 25 mg prašak za oralnu suspenziju dostupan je u kompletima koji sadrže 30 vrećica; svaka vrećica sadrži crvenkasto-smeđi do žuti prašak.
Revolade 50 mg film-coated tablets are round, biconvex, brown, debossed with ‘GS UFU’ and ‘50’ on one side.
Revolade 50 mg filmom obložene tablete su okrugle, bikonveksne, smeđe tablete s utisnutim oznakama ‘GS UFU’ i ‘50’ na jednoj strani.
Revolade 75 mg film-coated tablets are round, biconvex, pink, debossed with ‘GS FFS’ and ‘75’ on one side.
Revolade 75 mg filmom obložene tablete su okrugle, bikonveksne, ružičaste tablete s utisnutim oznakama ‘GS FFS’ i ‘75’ na jednoj strani.
Revolade can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment.
Revolade se također može koristiti za liječenje sniženog broja trombocita (trombocitopenija) u odraslih s infekcijom virusom hepatitisa C (HCV), ako su imali problema s nuspojavama dok su bili liječeni interferonom.
Revolade is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year and above who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).
Revolade je indiciran za liječenje bolesnika u dobi od 1 godine i starijih s kroničnom imunom (idiopatskom) trombocitopeničnom purpurom (ITP), koji su refrakterni na druge vidove liječenja (npr. kortikosteroide, imunoglobuline) (vidjeti dijelove 4.2 i 5.1).
Revolade is medicine that contains the active substance eltrombopag.
Revolade je lijek koji sadrži djelatnu tvar eltrombopag.
Revolade is not recommended for use in children under the age of one year with chronic ITP due to insufficient data on safety and efficacy.
Revolade se ne preporučuje za primjenu u djece mlađe od godinu dana s kroničnim ITP-om zbog nedostatnih podataka o sigurnosti i djelotvornosti.
Revolade is used for the treatment of:
Revolade se primjenjuje u odraslih osoba za liječenje:
Revolade is used in patients aged 1 year and above who do not respond to treatment with medicines such as corticosteroids or immunoglobulins; thrombocytopenia in adult patients with chronic (long-term) hepatitis C, a disease of the liver caused by infection with the hepatitis C virus, when the severity of thrombocytopenia is preventing antiviral therapy; acquired severe aplastic anaemia (a disease in which the bone marrow does not make enough blood cells) in adult patients.
Lijek Revolade primjenjuje se u bolesnika u dobi od jedne godine i starijih bolesnika koji ne odgovaraju na terapiju lijekovima poput kortikosteroida ili imunoglobulina; trombocitopenije u odraslih bolesnika s kroničnim (dugotrajnim) hepatitisom C, bolešću jetre koja je uzrokovana virusom hepatitisa C, ako težina trombocitopenije onemogućuje terapiju protuvirusnim lijekovima; stečene teške aplastične anemije (bolesti kod koje koštana srž ne proizvodi dovoljno krvnih stanica) u odraslih bolesnika.
Revolade is used in patients who did not respond to or had received multiple courses of immunosuppressive therapy (medicines that lower the body’s immune defences) and cannot receive haematopoietic (blood) stem cell transplantation.
Lijek Revolade primjenjuje se u bolesnika koji nisu odgovorili na imunosupresivnu terapiju (lijekove koji snižavaju imunosnu obranu tijela) ili su prethodno primili nekoliko ciklusa te terapije te koji ne mogu primiti transplantirane hematopoetske (krvne) matične stanice.
Revolade is used to treat a bleeding disorder called immune (idiopathic) thrombocytopenic purpura (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.
Revolade se može koristiti u liječenju poremećaja zgrušavanja krvi tj. krvarenja koje zovemo imuna (idiopatska) trombocitopenična purpura (ITP) u bolesnika (u dobi od 1 godine i stariji) koji su već uzimali druge lijekove (kortikosteroide ili imunoglobuline), a bez odgovarajućeg učinka.
Revolade may also be used to treat adult patients with low blood counts caused by severe aplastic anaemia (SAA).
Revolade se može koristiti i za liječenje odraslih bolesnika s niskim razinama krvnih stanica uzrokovanim teškom aplastičnom anemijom.
Revolade powder must be mixed only with water at room temperature.
Revolade prašak smije se miješati samo s vodom na sobnoj temperaturi.
Revolade should be interrupted if platelet counts increase to > 250,000/μl.
Liječenje lijekom Revolade treba prekinuti ako broj trombocita poraste > 250 000/μl.
Revolade was also effective at maintaining adequate levels of platelets in the extension phase of the study.
Lijek Revolade također bio djelotvoran u održavanju odgovarajućih razina trombocita u fazi produžetka ispitivanja.
REYATAZ 100 mg hard capsules are supplied in bottles of 60 capsules.
REYATAZ 100 mg tvrde kapsule isporučuju se u bočicama sa 60 kapsula.
REYATAZ 150 mg hard capsules are supplied in bottles of 60 capsules.
REYATAZ 150 mg tvrde kapsule isporučuju se u bočicama sa 60 kapsula.
REYATAZ 50 mg oral powder
REYATAZ 50 mg oralni prašak
REYATAZ 50 mg oral powder Atazanavir
REYATAZ 50 mg oralni prašak atazanavir
REYATAZ capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV- 1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).
REYATAZ kapsule, koje se primjenjuju istovremeno s niskom dozom ritonavira, indicirane su u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih i pedijatrijskih bolesnika u dobi od 6 godina i starijih, koji su zaraženi virusom HIV 1 (vidjeti dio 4.2).
REYATAZ given without ritonavir should not be considered in patients treated with a backbone regimen containing tenofovir disoproxil fumarate and with other concomitant medications that reduce atazanavir bioavailability (see section 4.5 In case of withdrawal of ritonavir from the recommended atazanavir boosted regimen) or in case of perceived challenging compliance.
Primjena lijeka REYATAZ bez ritonavira ne smije se razmatrati u bolesnika liječenih osnovnim režimom koji sadrži tenofovirdizoproksilfumarat i drugim istovremeno primjenjivanim lijekovima koji smanjuju bioraspoloživost atazanavira (vidjeti odlomak 'Ako se ritonavir izostavi iz preporučenog režima liječenja atazanavirom pojačanim ritonavirom' u dijelu 4.5), kao ni u bolesnika za koje se smatra da bi mogli imati poteškoća s pridržavanjem liječenja.
REYATAZ is also available as an oral powder for use in children at least 3 months old and weighing at least 5 kg.
REYATAZ je također dostupan u obliku oralnog praška za primjenu kod djece od najmanje 3 mjeseca starosti i tjelesne težine od najmanje 5 kg.
REYATAZ may increase plasma levels of carbamazepine due to CYP3A4 inhibition.
Zbog inhibicije CYP3A4, primjena lijeka REYATAZ može povisiti razine karbamazepina u plazmi.
REYATAZ oral powder must be taken with ritonavir and has to be taken with food.
REYATAZ oralni prašak mora se uzimati s ritonavirom i s hranom.
REYATAZ should be discontinued if severe rash develops.
Ako se razvije teški osip, primjenu lijeka REYATAZ treba prekinuti.
REYATAZ/ritonavir is co-
primjenjuje istovremeno s
REYATAZ/ritonavir may increase plasma levels of carbamazepine due to CYP3A4 inhibition.
Zbog inhibicije CYP3A4, primjena lijeka REYATAZ/ritonavira može povisiti razine karbamazepina u plazmi.
REYATAZ/ritonavir with other
REYATAZ/ritonavira i drugih
REYATAZ/ritonavir, it is
REYATAZ/ritonavirom
REYATAZ/ritonavir, the
REYATAZ/ritonavira,
Reye’s syndrome is a very rare disease which can be fatal.
Reyeov sindrom je vrlo rijetka bolest koja može biti smrtonosna.
Reye’s Syndrome is a very rare disease which can be fatal.
Reyeov sindrom je vrlo rijetka bolest koja može imati smrtni ishod.
Reykjavíkurvegi 76-78
Reykjavíkurvegi 76 78
Reykjavíkurvegi 76-78 IS-220 Hafnarfjörður Iceland
Reykjavíkurvegi 76 78 IS-220 Hafnarfjörður Island
Reykjavíkurvegur 76-78 IS-220 Hafnarfjörður Iceland
Reykjavíkurvegur 76-78, IS-220 Hafnarfjörður Island
RF emissions CISPR 11
RF emisije CISPR 11
Rhabdomiolysis (N)
rabdomioliza (N)
Rhabdomyol ysis11
rabdomioliza11
Rhabdomyoly sis
rabdomioliza
Rhabdomyolys is11
rabdomioliza11
Rhabdomyolysis
rabdomioliza11
Rhabdomyolysis (may affect up to 1 in 100 people) – is breakdown of muscle fibres that can lead to kidney damage.
Rabdomioliza (može se javiti u do 1 na 100 osoba) – propadanje mišićnih vlakana koje može uzrokovati oštećenje bubrega.
Rhabdomyolysis and blood creatine phosphokinase increased*
Rabdomioliza i povišena kreatin fosfokinaza u krvi
Rhabdomyolysis has been observed in patients experiencing skin and/or liver reactions associated with nevirapine use.
Rabdomioliza povezana s primjenom nevirapina opažena je u bolesnika s kožnim i/ili jetrenim reakcijama.
Rhabdomyolysis has been observed in patients experiencing skin and/or liver reactions associated with Viramune use.
Opažena je rabdomioliza kod bolesnika s kožnim i/ili jetrenim reakcijama povezanim s primjenom Viramunea.
Rhabdomyolysis has been observed in patients experiencing skin and/or liver reactions associated with Viramune use.
Opažena je rabdomioliza povezana kod bolesnika s kožnim i/ili jetrenim reakcijama povezanim s primjenom Viramunea.
Rhabdomyolysis has been observed in patients experiencing skin and/or liver reactions associated with Viramune use.
Opažena je rabdomioliza u bolesnika s kožnim i/ili jetrenim reakcijama povezanim s primjenom Viramunea.
Rhabdomyolysis has been reported in patients taking trametinib alone or in combination with dabrafenib.
U bolesnika koji su uzimali trametinib sam ili u kombinaciji s dabrafenibom prijavljena je rabdomioliza.
Rhabdomyolysis Myalgia Stiffness
rabdomioliza mialgija ukočenost
Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson’s disease.
Rabdomioliza kao posljedica teških diskinezija ili neuroleptičkog malignog sindroma (NMS) rijetko je opažena u bolesnika s Parkinsonovom bolešću.
Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson’s disease.
U bolesnika s Parkinsonovom bolešću rijetko je opažena rabdomioliza uslijed teških diskinezija ili neuroleptičkog malignog sindroma (NMS).
Rhabdomyolysis which is the breakdown of muscle fibres that leads to the release of muscle fibre contents (myoglobin) into the bloodstream, seen as muscle pain, being sick, being confused, an abnormal heart rate and rhythm, and possibly dark urine increase in eosinophils (a type of white blood cell).
Rabdomioliza što je propadanje mišićnih vlakana što dovodi do otpuštanja sadržaja mišićnih vlakana (mioglobina) u krvotok, što se očituje kao bol u mišićima, povraćanje, zbunjenost, nenormalna brzina otkucaja i ritam srca, a moguće i tamna mokraća porast eozinofila (vrsta bijelih krvnih stanica).
rhabdomyolysis) (see sections 4.3
rabdomiolizu) (vidjeti dijelove 4.3 i
Rhabdomyolysis*
rabdomioliza
Rhabdomyolysis*, myositis*
rabdomioliza*, miozitis
rhabdomyolysis,
rabdomioliza,
Rhabdomyolysis, blood creatine phosphokinase increased (see Post – Marketing Data)
Rabdomioliza, povišenje kreatin fosfokinaze u krvi (vidjeti podatke nakon stavljanja lijeka na tržište)
rhabdomyolysis, myositis, back pain, muscle twitching, neck pain
rabdomioliza, miozitis, bol u leđima, trzanje mišića, bol u vratu
Rhabdomyolysis, myositis, leg cramps, back pain
rabdomioliza, miozitis, grčevi u nogama, bol u leđima
Rhabdomyolysis, myositis, rheumatoid arthritis
rabdomioliza, miozitis, reumatoidni artritis
Rhabdomyolysis, osteonecrosis
Rabdomioliza, osteonekroza
rhabdomyolysis, osteonecrosis, muscle inflammation, tendonitis, arthritis
rabdomioliza, osteonekroza, upala mišića, tendinitis, artritis
Rhabdomyolysis, which can be associated with acute renal failure secondary to myoglobinuria, myopathy (see section 4.4); myositis, polymyositis.
rabdomioliza, koja može biti povezana s zatajenjem bubrega uslijed mioglobinurije, miopatija (vidjeti dio 4.4); miozitis, polimiozitis.
rhabdomyolysis.
rabdomiolizu.
Rhabdomyolysis/Blood creatine phosphokinase increased
Rabdomioliza/povišena kreatin fosfokinaza u krvi
Rhabdomyolysis11
Stariji bolesnici:
rhabdomyolysis2
rabdomioliza2
rhabdomyolysis2, muscular weakness2
rabdomioliza2, mišićna slabost2
Rhabdomyolysis3 **
Rabdomioliza3
rhabdomyolysisc, posture abnormalc
rabdomiolizac, nenormalno držanjec
rhabdomyolysise,
slabost
rhabdomyolysise, blood creatine phosphokinase increased, posture abnormale, joint swelling, muscular weakness
indrom apneje pri spavanjue, hiperventilacijae,
RHD type 2 virus differs from the classic form of RHD virus since the course of disease is more prolonged, deaths occur later and over a longer period and there are more deaths in young rabbits than in adults.
RHDV tipa 2 razlikuje se od klasičnog soja RHDV-a jer je tijek bolesti dulji, do smrti dolazi kasnije i tijekom duljeg razdoblja i zabilježen je veći stupanj smrtnosti u mladih kunića nego u odraslih.
Rheumatoid arthritis
reumatoidnog artritisa
Rheumatoid arthritis (RA)
Reumatoidni artritis (RA)
Rheumatoid Arthritis (RA)
reumatoidnog artritisa
Rheumatoid arthritis aggravated
Egzacerbacija reumatoidnog artritisa
Rheumatoid arthritis aggravated
pogoršan reumatoidni artritis
Rheumatoid arthritis patients demonstrate a comparable (to healthy subjects) decrease of absolute neutrophil counts following tocilizumab administration (see section 4.8).
Kod bolesnika s reumatoidnim artritisom je nakon primjene tocilizumaba primijećeno usporedivo (u odnosu na zdrave ispitanike) smanjenje apsolutnog broja neutrofila (vidjeti dio 4.8).
rheumatoid arthritis,
reumatoidnog artritisa,
Rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
Reumatoidni artritis, granulomatoza s poliangitisom i mikroskopski poliangitis
rheumatoid arthritis, kidney problems,
reumatoidni artritis, tegobe s bubrezima,
rheumatoid arthritis, psoriasis
reumatoidni artritis, psorijaza
Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis The usual dose is 50 mg once a week as an injection under the skin.
Reumatoidni artritis, psorijatični artritis i aksijalni spondioloartritis uključujući ankilozantni spondilitis Uobičajena doza je 50 mg primijenjeno jednom tjedno injekcijom pod kožu.
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
Reumatoidni artritis, psorijatični artritis, ankilozantni spondilitis ili aksijalni spondiloartritis bez radiološkog dokaza ankilozantnog spondilitisa
Rheumatoid arthritis1
Reumatoidn i artritis1
Rheumatoid arthritis1
Reumatoidni artritis1
Rheumatoidis arthritis:
Reumatoidni artritis:
Rheumocam 1.5 mg/ml oral suspension for dogs
Rheumocam 1,5 mg/ml peroralna suspenzija za pse Meloksikam
Rheumocam 330 mg granules for horses
Rheumocam 330 mg granule za konje
Rheumocam 330 mg granules for horses.
Rheumocam 330 mg, granule za konje.
Rheumocam 330 mg, granules for horses.
Rheumocam 330 mg granule za konje.
Rheumocam 330 mg, granules for horses. meloxicam
Rheumocam 330 mg, granule za konje. meloksikam.
Rheumocam 5 mg/ml solution for injection for cats and dogs Meloxicam
Rheumocam 5 mg/ml otopina za injekcije za pse i mačke Meloksikam
Rheumocam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Rheumocam sadrži meloksikam, koji pripada skupini lijekova zvanih nesteroidni protuupalni lijekovi (NSAID-ovi).
Rheumocam is a veterinary medicine that contains the active substance meloxicam.
Rheumocam je veterinarsko-medicinski proizvod koji sadrži djelatnu tvar meloksikam.
Rheumocam is a ‘generic’, which means that Rheumocam is similar to a ‘reference veterinary medicine’ already authorised in the EU (Metacam).
Rheumocam je "generički lijek", što znači da je Rheumocam sličan "referentnom veterinasko- medicinskom proizvodu" koji je već odobren u EU (Metacam).
Rheumocam meloxicam
Rheumocam meloksikam
Rheumocam must not be administered in conjunction with other NSAIDs or glucocorticosteriods.
Rheumocam se ne smije primjenjivati zajedno s drugim nesteroidnim protuupalnim lijekovima (NSAID) ili glukokortikosteroidima.
Rheumocam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Rheumocam se ne smije primjenjivati zajedno s drugim nesteroidnim protuupalnim lijekovima ili glukokortikosteroidima.
Rheumocam must not be used in animals with liver, heart or kidney problems, bleeding disorders, or suffering from irritation or ulcers of the digestive tract.
Rheumocam se ne smije koristiti kod životinja s problemima jetre, srca ili bubrega, s poremećajima krvarenja ili onih koje pate od iritacije ulkusa u probavnom traktu.
Rheumocam must not be used in dogs or horses less than six weeks of age or in cattle less than one week of age when used in the treatment of diarrhoea.
Rheumocam se ne smije koristiti kod pasa ili konja mlađih od šest mjeseci ili u goveda mlađih od tjedan dana ako se koristi za liječenje proljeva.
Rheumocam should not be used in pregnant or lactating horses and dogs, but it can be used during pregnancy and lactation for cattle and pigs.
Rheumocam se ne smije primjenjivati u gravidnih kobila i kuja ili istih u laktaciji, no može se koristiti tijekom trudnoće i laktacije kod goveda i svinja.
Rhinalgia, nasal discomfort (including nasal burning, nasal irritation, and nasal soreness), nasal dryness.
bol u nosu, neugoda u nosu (uključujući peckanje nosa, iritaciju nosa i osjetljivost nosa), suhoća nosa
RHINISENG suspension for injection for pigs
RHINISENG suspenzija za injekciju za svinje
rhinitis
curenje nosa
rhinitis
infiltracija pluća
Rhinitis*
Rinitis
rhinitis,
rinitis
Rhinitis, sinusitis, epistaxis, nasal discomfort, rhinorrhea, dry throat, hyposmia
rinitis, sinusitis, epistaksa, nelagoda u nosu, rinoreja, suho grlo, hiposmija
Rhinitis2
Rinitis2
Rhinorrhea
Rinoreja
rhinorrhea, cough nonproductive
neproduktivan kašalj
Rhinorrhoea
astma
Rhinorrhoea
kašalj, rinoreja
Rhinorrhoea
rinoreja
Rhinorrhoea Common
Rinoreja Često
Rhinorrhoea Dysphonia Oropharyngeal pain Epistaxis
Orofaringealna bol Epistaksa
rhinorrhoea dyspnoea pulmonary arterial hypertension┼
rinoreja dispneja plućna arterijska hipertenzija┼
Rhinorrhoea Epistaxis
rinoreja, epistaksa
Rhodor 7046R antifoam - Tetracycline (Hcl) HD - EVA (Ethyl Vinyl Acetate) - White soft paraffin - Paraffin 50/52° C - Seah Saur - Natural fish aroma
Rhodor 7046R antifoam - tetraciklin (HCl) HD - EVA (vinil acetat etil) - bijeli meki parafin - parafin 50/52°C - seah saur - prirodna aroma ribe.
Ribavirin
Deksametazon
Ribavirin
i ribavirin
Ribavirin (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n = 505).
Ribavirin (1000/1200 mg/dan) + interferon alfa-2b (3 MIU triput na tjedan) (n=505).
Ribavirin (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n=505).
Ribavirin Mylan (1000/1200 mg/dan) + interferon alfa-2b (3 MIU triput na tjedan) (n = 505).
Ribavirin (1,000/1,200 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) (n = 514).
Ribavirin (1000/1200 mg/dan) + peginterferon alfa-2b (1,5 mikrograma/kg/tjedan tijekom mjesec dana, a zatim 0,5 mikrograma/kg/tjedan tijekom sljedećih 11 mjeseci) (n=514),
Ribavirin (1,000/1,200 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) (n=514).
Ribavirin Mylan (1000/1200 mg/dan) + peginterferon alfa-2b (1,5 mikrograma/kg/tjedan tijekom mjesec dana, a zatim 0,5 mikrograma/kg/tjedan tijekom sljedećih 11 mjeseci) (n = 514),
ribavirin (800 mg)
IU triput na tjedan) + ribavirin (800 mg)
Ribavirin (800 mg/day) + interferon alfa- 2b (3 MIU TIW)
Ribavirin (800 mg/dan) + interferon alfa-2b (3 MIU triput na tjedan)
Ribavirin (800 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week) (n = 511).
Ribavirin (800 mg/dan) + peginterferon alfa-2b (1,5 mikrograma/kg/tjedan) (n=511),
Ribavirin (800 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week) (n=511).
Ribavirin Mylan (800 mg/dan) + peginterferon alfa-2b (1,5 mikrograma/kg/tjedan) (n = 511),
Ribavirin 15 mg/kg/day
Ribavirin 15 mg/kg/dan
Ribavirin 15 mg/kg/day
Ribavirin Mylan 15 mg/kg/dan
Ribavirin 800 mg
i ribavirin 800 mg